

**Application  
for  
United States Letters Patent**

**To all whom it may concern:**

**Be it known that I**

**David J. Pinsky**

**have invented certain new and useful improvements in**

**CD39/ECTO-ADPASE FOR TREATMENT OF THROMBOTIC AND ISCHEMIC DISORDERS**

**of which the following is a full, clear and exact description.**

**CD39/ECTO-ADPASE FOR TREATMENT  
OF THROMBOTIC AND ISCHEMIC DISORDERS**

The invention described herein was made in the course of work done under Grant Nos. HL-47073, HL-46403, HL-07423 (AJM, MJB, JHFD), HL-59488 and HL-55397 (DJP) and NS 02038 (ESC) Department of Veterans Affairs and from National Institutes of Health. Therefore, the United States Government has certain rights in this invention.

Throughout this application, various publications are referenced by numbers. Full citations for these publications may be found listed numerically at the end of the specification immediately preceding the claims. The disclosures of these publications in their entireties are hereby incorporated by reference into this application in order to more fully describe the state of the art as known to those skilled therein as of the date of the invention described and claimed herein.

**Background of the Invention**

Stroke is the third leading cause of death and the main cause of permanent morbidity in the United States, affecting over 450,000 patients annually<sup>1</sup>. Recent studies in a murine model of ischemic stroke demonstrated a pivotal role for platelets in progressive microvascular thrombosis distal to the primary obstruction of a major cerebrovascular tributary<sup>2</sup>. This progressive microvascular thrombosis is characterized by distal platelet and fibrin accumulation, resulting in postischemic hypoperfusion ("no re-flow") and neuronal injury<sup>2</sup>. While leukocyte adhesion receptors and recruited neutrophils contribute to postischemic hypoperfusion, postischemic hypoperfusion cannot be completely abrogated because even in the absence

of neutrophils, progressive microvascular thrombosis persists<sup>3,4</sup>. Two thrombolytic agents, recombinant tissue-type plasminogen activator (rtPA) and pro-urokinase, have been used for treatment of stroke. However, their therapeutic utility is limited due to risk of symptomatic and fatal intracranial hemorrhage<sup>5</sup>. In the United States, less than 1% of patients presenting to community hospitals with acute ischemic stroke receive rtPA<sup>6</sup>. Inhibition of the final common pathway of platelet accumulation, via blockade of glycoprotein IIb/IIIa receptor-mediated platelet-platelet interactions, does reduce microvascular thrombosis in experimental stroke<sup>2</sup>. However, as with thrombolytic agents, small excesses of a GPIIb/IIIa receptor blocker culminated in serious intracerebral hemorrhage. It is therefore important to identify novel strategies for inhibition of platelet function in acute stroke that will reduce intravascular thrombosis without increasing risk of intracerebral hemorrhage.

Summary of the Invention

The present invention provides a method of treating or preventing thrombotic or ischemic disorders in a subject which comprises administering an agent to the subject, wherein the agent inhibits platelet aggregation by increasing ADP catabolism. The present invention also provides a method for determining whether a compound inhibits platelet aggregation by increasing ADP catabolism so as to treat or prevent thrombotic or ischemic disorders in a subject, comprising: (a) inducing thrombotic or ischemic disorders in an animal, which animal is an animal model for thrombotic or ischemic disorders; (b) measuring the stroke outcome in said animal, (c) measuring platelet deposition and/or fibrin deposition in ischemic tissue, and (d) comparing the stroke outcome in step (b) and the platelet deposition and/or fibrin deposition with that of the animal model in the absence of the compound so as to identify a compound capable of treating or preventing thrombotic or ischemic disorders in a subject.

25

30

**Brief Description of the Figures**

**Figures 1A-1F:** Effects of saline (control), aspirin or CD39 on the aggregation of murine platelets in response to: **(A)** ADP 2.5  $\mu$ M; **(B)** collagen 2.5  $\mu$ g/mL; **(C)** ADP 10  $\mu$ M; **(D)** collagen 10  $\mu$ g/mL; or **(E)** sodium arachidonate (0.1 mM). The % inhibition of platelet aggregation is shown in **(F)**. Agents were administered to mice 45 minutes prior to harvest of blood, and preparation of platelet-rich plasma for the indicated studies.

**Figure 2:** Bleeding times in control, aspirin-treated, CD39-treated, or CD39 null mice.

**Figures 3A-3E:** Effect of CD39 on stroke outcomes, and comparison with aspirin. **(A)** Cerebral blood flow; **(B)** cerebral infarction volume; **(C)** Neurological deficit stroke; **(D)** mortality; **(E)** intracerebral hemorrhage.

**Figure 4.** Covariate plot of cerebral infarct volume vs intracerebral hemorrhage: Comparison of vehicle (saline) with aspirin (ASA, 5 mg/kg prior to stroke), CD39 (4 and 8 mg/kg prior to stroke), and CD39 (8 mg/kg, 3 hours following stroke induction).

**Figures 5A-5B:** **(A)** Effect of CD39 on platelet deposition in stroke; **(B)** Effect of CD39 on fibrin accumulation in stroke; A positive fibrin control is shown in the leftmost lane. Ipsilat.=ipsilateral (i.e., ischemic) hemisphere. Contralat.=nonischemic left hemisphere.

**Figures 6A-6E.** Comparison of stroke outcomes: control (C57BL/6J x 129/J F1) mice (n=6), CD39<sup>-/-</sup> mice (n=5), and CD39<sup>-/-</sup> mice "reconstituted" with CD39 (n=6). Cerebral

blood flow **(A)** cerebral infarct volume **(B)** neurological score **(C)** mortality, and **(D)** intracerebral hemorrhage **(E)** (\* $p < 0.05$ , † $p < 0.01$ , ‡ $p < 0.001$ ).

5

10

15

20

25

30

**Detailed Description of the Invention**

The present invention provides a method for treating or preventing stroke in a subject wherein the subject is susceptible to intracranial hemorrhaging, comprising  
5 administering a CD39 polypeptide (SEQ ID NO:1) or an active fragment thereof which inhibits adenosine diphosphate-mediated platelet aggregation by increasing adenosine diphosphate catabolism to the subject.

10 In one embodiment of the method, the active fragment is CD39 polypeptide is a mutated or a truncated form of CD39 polypeptide.

In another embodiment of the method, the active fragment is  
15 soluble CD39 (SEQ ID NO:2).

In another embodiment of the method, the CD39 polypeptide is a recombinant CD39 polypeptide having IL-2 as its leader sequence.  
20

In another embodiment of the method, the recombinant CD39 polypeptide lacks a transmembrane domain.

In another embodiment of the method, the active fragment  
25 comprises from amino acid number 1 to amino acid number 50 of SEQ ID NO.:2.

In another embodiment of the method, the active fragment of the CD39 polypeptide comprises about 20-80 amino acid  
30 residues of SEQ ID NO:1 which mimics the active site of CD39.

In one embodiment of the method, the CD39 polypeptide or its active fragment treats or prevents thrombotic or  
35 ischemic disorders in a subject without increasing bleeding

or intracerebral hemorrhage.

As used herein, the term "ADP" means adenosine diphosphate.

5

As used herein, "ischemic and thrombotic disorders" encompass pulmonary embolism, lung ischemia, limb or gut ischemia, myocardial ischemia, post surgical vasculopathy, postangioplasty stenosis, shunt/fistula remodeling or thrombosis, cerebral ischemia, or ischemia of other organs or tissues.

10

As used herein, the term "ischemic disorder" encompasses and is not limited to a peripheral vascular disorder, a venous thrombosis, a pulmonary embolus, a myocardial infarction, a transient ischemic attack, lung ischemia, unstable angina, a reversible ischemic neurological deficit, adjunct thromolytic activity, excessive clotting conditions, reperfusion injury, sickle cell anemia, a stroke disorder or an iatrogenically induced ischemic period such as angioplasty.

15

20

As used herein, the term "thrombotic disorder" encompasses disorders caused by the formation, development or presence of a blood clot or a blood coagulation which is located inside of a patient or inside of an extracorporeal circuit or system which circulates blood of the patient. Thrombotic disorder also encompasses disorders caused by the presence of a thrombus which includes a blood clot partially or fully occluding a blood vessel or formed in a heart cavity or by the activation of a plasmatic coagulation system in a patient which includes the production of fibrin, emeshed platelets, fibrin degradation product, protein C, free protein S, coagulation factor II, immunoglobulin G or albumin in the patient. Thrombotic

25

30

35



disorder also encompasses disorders cause by the formation of white thrombus which may be composed of platelets and fibrin and is relatively poor in erythrocytes, a disseminated fibrin deposit thrombus or a red thrombus which may be composed of red cells and fibrin.

In another embodiment of the method, the CD39 polypeptide or its active fragment can be replaced by a peptide, an enzyme, a pseudo enzyme, a catalyst, a peptidomimetic compound, a glycosylated peptide, a small molecule, a mutated peptide or an antibody.

As used herein, a polypeptide is an amino acid polymer of amino acids linked together by peptide bonds; a nucleic acid is a deoxyribonucleotide or ribonucleotide polymer of nucleotides linked together by phosphodiester bonds; an antisense nucleic acid is a nucleic acid that is the reverse complement of another nucleic acid which may be capable of inhibiting transcription or translation of the other nucleic acid.

In another embodiment of the method, the the CD39 polypeptide or its active fragment agent comprises a CD39 polypeptide (abbreviated as CD39) or a variant thereof.

Variants in amino acid sequence of CD39 are produced when one or more amino acids in naturally occurring CD39 is substituted with a different natural amino acid, an amino acid derivative, a synthetic amino acid, an amino acid analog or a non-native amino acid. Particularly preferred variants include homologous CD39 of humans or of different species of animals. Variants of a CD39 may include biologically active fragments of naturally occurring CD39, wherein sequences of the variant differ from the wild type CD39 sequence by one or more conservative amino acid

substitutions. Such substitutions typically would have minimal influence on the secondary structure and hydrophobic nature of the CD39. The amino acid sequences of CD39 and one variant of CD39 have been previously  
5 determined and are the following:

MEDTKESNVKTFCSKNILAILGFSSIIAVIALAVGLTQNKALPENVKYGIVLDAGS  
SHTSLYIIKWPAEKENDTGCVHQQVEECRVKGPISKFVQKVNEIGIYLTDCMERARE  
VIPRSQHQETPVYLGATAGMRLLRMESEELADRVLDVVERSLSNYPFDFQGARIITG  
10 QEEGAYGWITINYLLGKFSQKTRWFSIVPYETNNQETFGALDLGGASTQVTFVPQNO  
TIESPDNALQFRLYGKDYNVYTHSFLCYGKDQALWQKLAKDIQVASNEILRDPCFHP  
GYKKVVNVSDLYKTPCTKRFEMTLFPQQFEIQGIGNYQQCHQSILELFNTSYCPYSQ  
CAFNGIFLPPLQGDFGAFSAFYFVMKFLNLTSEKVSQEKVTEMMKKFCAQPWEEIKT  
SYAGVKEKYLSEYCFSGTYILSLLLQGYHFTADSWEHIHFIGKIQGSDAGWTLGYML  
15 NLTNMIPAEQPLSTPLSHSTYVFLMVLFSLVLTVAIIGLLIFHKPSYFWKDMV  
(SEQ ID NO:1)

TQNKALPENVKYGIVLDAGSSHTSLYIIKWPAEKENDTGCVHQQVEECRVKGPISKF  
VQKVNEIGIYLTDCMERAREVIPRSQHQETPVYLGATAGMRLLRMESEELADRVLDV  
20 VERSLSNYPFDFQGARIITGQEEGAYGWITINYLLGKFSQKTRWFSIVPYETNNQET  
FGALDLGGASTQVTFVPQNOQTIESPDNALQFRLYGKDYNVYTHSFLCYGKDQALWQK  
LAKDIQVASNEILRDPCFHPGYKKVVNVSDLYKTPCTKRFEMTLFPQQFEIQGIGNY  
QQCHQSILELFNTSYCPYSQCAFNGIFLPPLQGDFGAFSAFYFVMKFLNLTSEKVSQ  
EKVTEMMKKFCAQPWEEIKTSYAGVKEKYLSEYCFSGTYILSLLLQGYHFTADSWEH  
25 IHFIGKIQGSDAGWTLGYMLNLTNMIPAEQPLSTPLSHST  
(SEQ ID NO:2)

Variants may also have sequences which differ by one or more non-conservative amino acid substitutions, deletions  
30 or insertions which do not abolish the biological activity associated with CD39. Conservative substitutions (substituents) typically include the substitution of one amino acid for another with similar characteristics such as substitutions within the following groups: valine, glycine;  
35 glycine, alanine; valine, isoleucine; aspartic acid,

glutamic acid; asparagine, glutamine; serine, threonine; lysine, arginine; and phenylalanine, tyrosine. The non-polar (hydrophobic) amino acids include alanine, leucine, isoleucine, valine, proline, phenylalanine, tryptophan and methionine. The polar neutral amino acids include glycine, serine, threonine, cysteine, tyrosine, asparagine and glutamine. The positively charged (basic) amino acids include arginine, lysine and histidine. The negatively charged (acidic) amino acids include aspartic acid and glutamic acid.

A CD39 variant of this invention includes a CD39 varied by changes such as insertions, deletions and substitutions, either conservative or nonconservative where such changes might provide for certain advantages in their use such as increased potency, bioavailability, stability or decreased toxicity or degradation under physiological conditions.

One embodiment of the present invention is a truncated variant of the CD39 which variant is capable of increasing adenosine diphosphate catabolism or having improved availability or decreased immunogenicity or increased activity.

In other embodiments, variants with amino acid substitutions which are less conservative may also result in desired derivatives of CD39, e.g., by causing desirable changes in charge, conformation and other biological properties. Such substitutions would include for example, substitution of hydrophilic residue for a hydrophobic residue, substitution of a cysteine or proline for another residue, substitution of a residue having a small side chain for a residue having a bulky side chain or substitution of a residue having a net positive charge for a residue having a net negative charge. When the result of

a given substitution cannot be predicted with certainty, the derivatives may be readily assayed according to the methods disclosed herein to determine the presence or absence of the desired characteristics.

5

Just as it is possible to replace substituents of the scaffold (i.e., amino acids which make up the CD39), it is also possible to substitute functional groups which decorate the scaffold with groups characterized by similar features (i.e., R-groups which are part of each amino acid). These substitutions will initially be conservative, i.e., the replacement group will have approximately the same size, shape, hydrophobicity and charge as the original group. Non-sequence modifications may include, for example, 10 in vivo or in vitro chemical derivatization of portions of naturally occurring CD39, as well as changes in acetylation, methylation, phosphorylation, carboxylation or glycosylation.

15

20 In a further embodiment the CD39 is modified by chemical modifications in which activity is preserved. For example, the CD39 may be aminated, sulfated, singly or multiply halogenated, alkylated, carboxylated, or phosphorylated. The CD39 may also be singly or multiply acylated, such as 25 with an acetyl group, with a farnesyl moiety, or with a fatty acid, which may be saturated, monounsaturated or polyunsaturated. The fatty acid may also be singly or multiply fluorinated. The invention also includes methionine analogs of CD39, for example the methionine sulfone and methionine sulfoxide analogs. The invention 30 also includes salts of CD39, such as ammonium salts, including alkyl or aryl ammonium salts, sulfate, hydrogen sulfate, phosphate, hydrogen phosphate, dihydrogen phosphate, thiosulfate, carbonate, bicarbonate, benzoate, 35 sulfonate, thiosulfonate, mesylate, ethyl sulfonate and

30

35

benzensulfonate salts.

5 Variants of CD39 may also include peptidomimetic compounds of CD39. Such compounds are well known to those of skill in the art and are produced through the substitution of certain R groups or amino acids in the protein with non-natural replacements. Such substitutions may increase the stability, bioavailability, or activity of such CD39 compound.

10 In another embodiment of the method, the CD39 polypeptide is a recombinant CD39 polypeptide having IL-2 as its leader sequence. A different leader sequence may be used to drive the secretion of the protein.

15 In another embodiment of the method, the recombinant CD39 polypeptide lacks a transmembrane domain.

20 In another embodiment of the method, the agent comprises a biologically active fragment of the CD39 polypeptide or its variants thereof or a non-protein compound that augments ADP catabolism.

25 In another embodiment of the method, the active fragment of the CD39 polypeptide has 20-80 amino acid residues which mimics the active site of CD39 or its variants thereof.

30 In another embodiment of the method, the CD39 polypeptide or its active fragment can be replaced by a nucleic acid encoding CD39 or its variants or a biologically active fragment thereof.

35 In another embodiment of the method, the stroke is associated with pulmonary embolism, post surgical vasculopathy, postangioplasty stenosis, and shunt/fistula

remodeling or thrombosis.

5 In another embodiment of the method, the stroke is associated with lung ischemia, limb ischemia, gut ischemia, myocardial ischemia.

10 In another embodiment, the time of administration comprises from about 5 days before surgery or onset of the disorder to about 5 days after surgery or the onset of the disorder.

15 In another embodiment, the period of time comprises from about 1 hour before surgery or the onset of the disorder to about 12 hours after surgery or the onset of the disorder.

In another embodiment, the period of time comprises from about 12 hours before surgery or the onset of the disorder to about 1 hour after surgery or the onset of the disorder.

In another embodiment, the period of time comprises from about 1 hour before surgery or the onset of the disorder to about 1 hour after surgery or the onset of the disorder.

20 In one embodiment, the subject is a mammal. In another embodiment, the mammal is a human. In another embodiment, the amount of CD39 polypeptide or its active fragment administered comprises from about 75  $\mu\text{g/kg}$  to about 550  $\mu\text{g/kg}$ . In another embodiment, the amount comprises 300  $\mu\text{g/kg}$ .

25

In another embodiment of the method, the administration of the CD39 polypeptide or its active fragment occurs at the onset of stroke in a subject.

30 In another embodiment of the method, the administration of the CD39 polypeptide or its active fragment is prior to stroke onset in a subject.

35 In another embodiment of the method, the administration of

the CD39 polypeptide or its active fragment occurs after the stroke onset in a subject.

5 In another embodiment of the method, the CD39 polypeptide or its active fragment is administered in a dosage of 1-20 mg/kg of the subject's body weight.

10 In another embodiment of the method, the CD39 polypeptide or its active fragment is administered in a dosage of 4-8 mg/kg of the subject's body weight.

In another embodiment of the method, the subject is a mouse, a rat, a dog, a primate or a human.

15 In a further embodiment of the method, the CD39 polypeptide or its active fragment is administered with a pharmaceutically acceptable carrier.

20 The present invention also provides a method for determining whether a compound inhibits platelet aggregation by increasing ADP catabolism so as to treat or prevent thrombotic or ischemic disorders in a subject, comprising: (a) inducing thrombotic or ischemic disorders in an animal, which animal is an animal model for  
25 thrombotic or ischemic disorders; (b) measuring the stroke outcome in said animal, (c) measuring platelet deposition and/or fibrin deposition in ischemic tissue, and (d) comparing the stroke outcome in step (b) and the platelet deposition and/or fibrin deposition with that of the animal  
30 model in the absence of the compound so as to identify a compound capable of treating or preventing thrombotic or ischemic disorders in a subject.

35 In one embodiment of the method, the animal model comprises CD39-deficient mice; wherein the thrombotic or ischemic

disorders are induced by administering an agonist to said mice.

5 In another embodiment of the method, the compound treat or prevent thrombotic or ischemic disorders in a subject without increasing intracerebral hemorrhage or bleeding.

10 In another embodiment of the method, the stroke outcome is determined from the measurements of platelet deposition, bleeding time and infarction volume.

In another embodiment of the method, the compound can be administered orally or by injection.

15 In another embodiment of the method, the compound is identified by the method.

20 In another embodiment of the method, the administration of the compound is prior to stroke onset in the animal.

In yet another embodiment of the method, the administration of the compound occurs at the onset of stroke in the animal.

25 In a further embodiment of the method, the administration of the compound occurs after the stroke onset in the animal.

30 The present invention further provides a pharmaceutical composition comprising the compound of identified by the methods and a pharmaceutically acceptable carrier as an agent to treat thrombotic or ischemic disorders in a subject.

35 In one embodiment of the pharmaceutical composition, the



composition comprises CD39 and a pharmaceutically acceptable carrier

5 As used herein, the term "pharmaceutically acceptable carrier" encompasses any of the standard pharmaceutically acceptable carriers, such as phosphate buffered saline solution, water, emulsions such as oil/water emulsion or a triglyceride emulsion, various types of wetting agents, tablets, coated tablets and capsules. Typically, such  
10 carriers contain excipients such as starch, milk, sugar, certain types of clay, gelatin, stearic acid, talc, vegetable fats or oils, gums, glycols, or other known excipients. Such carriers may also include flavor and color additives or other ingredients.

15 By means of well-known techniques such as titration and by taking into account the observed pharmacokinetic characteristics of the agent in the individual subject, a skilled artisan can determine the appropriate dosages for  
20 treatment methods of the present invention.

Mutants or fragments of CD39 can be produced by known genetic engineering techniques, using as the starting material recombinant cDNA encoding CD39 in an appropriate  
25 cloning vector or using direct chemical synthesis.

This invention will be better understood from the Experimental Details which follow. These sections are set forth to aid in an understanding of the invention but are  
30 not intended to, and should not be construed to, limit in any way the invention as set forth in the claims which follow thereafter.

### Experimental Details

#### **Example 1: CD39/ecto-ADPase inhibits thrombosis and limits ischemic cerebral injury in wild type and reconstituted CD39 null mice**

Initial studies demonstrated a significant contribution of leukocyte adhesion receptors and recruited neutrophils to postischemic no-reflow, but even in the absence of neutrophils, postischemic no-reflow was not completely abrogated as progressive microvascular thrombosis ensued<sup>3, 4</sup>. More recent studies in a murine model of ischemic stroke demonstrated the cardinal role of platelets in progressive microvascular thrombosis distal to the site of primary obstruction of a major cerebrovascular tributary.<sup>2</sup> Progressive microvascular thrombosis, characterized by accumulation of platelets and fibrin at downstream sites, contributes to post-ischemic hypoperfusion (no reflow) and cerebral tissue damage<sup>2</sup>. Recent research has indicated that inhibition of the final common pathway of platelet accumulation, via blockage of glycoprotein IIb/IIIa receptor-mediated platelet-platelet interactions, could reduce microvascular thrombosis in stroke<sup>2</sup>. However, the therapeutic window for GP IIb/IIIa receptor blockade, similar to thrombolytic agents is narrow, with even small excesses dosing culminating devastating intracerebral hemorrhage.

When the integrity of the blood vessel wall is compromised, platelets adhere to collagen in the subendothelium, leading to platelet activation and the release of additional agonist: adenosine diphosphate (ADP), thromboxane (TXA<sub>2</sub>), and serotonin. Of these, ADP is the most important platelet agonist and recruiting agent present in the

microenvironment of the thrombus<sup>7</sup>. There are three primary mechanisms by which endothelial cells, under homeostatic conditions, maintain blood fluidity at the blood/vessel wall interface. These include the local generation of nitric oxide, release of eicosanoids, and expression of ectoADPase (CD39), a highly conserved enzyme which promotes ADP catabolism, thus potently inhibiting platelet aggregation<sup>8</sup>. Endothelial cells express CD39 constitutively. When recombinant CD39 was transfected into COS cells, they acquired the ability to inhibit ADP-induced platelet aggregation, establishing CD39 as a prime thromboregulatory enzyme<sup>9</sup>. Recently, CD39 was prepared in soluble form by deletion of two transmembrane domains and inclusion of a new leader sequence, and expressed in CHO cells<sup>11</sup>. This soluble CD39 (CD39) also blocked ADP-induced platelet aggregation *in vitro*<sup>11</sup>. The present studies were designed to elucidate the role of CD39 in the microvascular thrombosis of stroke, driven by the hypothesis that augmenting endogenous CD39 should inhibit ADP-mediated autoamplification of platelet recruitment in distal microvessels and thereby reduce accretion of thrombus stroke. The studies presented herein provide an improved method to use CD39 to inhibit microvascular thrombosis confer cerebroprotection in stroke without intracerebral hemorrhage.

**Abbreviations:** rtPA, recombinant tissue-type plasminogen activator; CBF, cerebral blood flow; ADP, adenosine diphosphate; TXA<sub>2</sub>, thromboxane A<sub>2</sub>; ICH, intracerebral hemorrhage.

**Mice:** Mice lacking CD39 were generated by homologous recombination in ES cells. Briefly, a gene targeting vector was created in which exons 3-5, containing Apyrase Conserved Regions 1-3 (ACR 1-3) were replaced with a PGKneo

cassette. The resulting targeting vector was introduced into 129 derived ES cells. ES clones carrying a CD39 allele disrupted by homologous recombination were identified by genomic Southern blot analyses and injected into blasdtocysts. The resulting chimeras were bred to C57BL/6 to generate mice heterozygous for the CD39 mutation (CD39+/-), which were subsequently intercrossed to generate mice deficient in CD39 (CD39-/- mice were born at the expected Mendelian frequency mice used throughout these experiments represent were on a background of 50% 129J; other mice used for experiments as indicated were CD39+/+ C57BL/6 mice or control C57BL/6/129J CD39+/+ mice (designated F1 controls: for clarity). Animals were 7-9 weeks of age and weighed between 22 and 26g.

**Materials:** Specific materials were acquired from the following sources. ADP, heparin (Sigma, St. Louis, MO) collagen (Hormon Chemie, Munchen, Germany); sodium arachidonate (Nu-Check Prep, Elysian, MN).

**Transient Middle Cerebral Artery Occlusion:** Mice were anesthetized (0.3 ml of 10 mg/mL ketamine and 0.5 mg/mL xylazine, IP) and positioned supine on a rectal temperature controlled operating surface (yellow Springs Instruments, Inc). Animal core temperature was maintained at  $37 \pm 2^\circ\text{C}$  during surgery and for 90 minutes after surgery. A midline neck incision was created to expose the right carotid sheath under the operating microscope (x6 to x40 zoom, Leica). The common carotid artery was isolated with 4-0 silk, and the occipital, pterygopalatine, and external carotid Arteries were each isolated and divided. MCAO was accomplished by advancing a 13-mm, heat-blunt tipped 6-0 nylon suture via an arteriotomy made in the external carotid stump. After placement of the occluding suture, the external carotid artery stump was cauterized to prevent

bleeding through the arteriotomy, and arterial flow was established. The duration of carotid occlusion never exceeded 3 minutes. After 45 minutes, the occluding suture and cautery was once again employed to prevent bleeding through the arteriotomy. The wound was closed with surgical staples. These procedures have previously described in detail<sup>25</sup>.

**Measurement of Cerebral Cortical Blood Flow:** Transcranial measurements of cerebral blood flow were made using laser Doppler (Permed, Inc. Piscataway, NJ) as previously described<sup>25</sup>. Using a 0.7 mm straight laser Doppler probe (model PF 303, Perimed) and previously published landmarks (2mm posterior to the bregma, 6mm to each side of the midline)<sup>25</sup>, relative cerebral blood flow measurement were made as follows; after anesthesia, immediately after occlusion, pre-reperfusion, immediate post-reperfusion, and at sacrifice. Data are expressed as the ratio of the Doppler signal intensity of the ischemic compared with the nonischemic hemisphere. The surgical procedure was considered to be technically adequate if a  $\geq 70\%$  reduction in cerebral blood flow was observed immediately after placement of the intraluminal occluding suture.

**Neurological Exam:** Twenty-four hours after surgery, mice were examined for neurological deficit using a modified four-tiered grading system published by Hata<sup>26</sup>. A score of 1 was given if the animal demonstrated spontaneous movements and extended both forelimbs when rolling supine (primitive Moro reflex); a score of two was given if the animal spontaneously circled clockwise when viewed from above; a score of three was given if the animal exhibited marginal activity and leaned to one side or had incomplete extension of the contralateral forelimb when rolled supine. A score of four was given if the animal exhibited no

spontaneous movements.

**Calculation of Infarct Volume:** After neurological examination, mice were anesthetized, and final cerebral blood flow measurements obtained. Mice were sacrificed and brains were removed and placed in a mouse brain matrix (Activational Systems Inc.) For 1 mm sectioning. Section were immersed in 2% TTC (Sigma) in .9% saline, incubated for 12 minutes at 37°C. Infarcted brain was stained as an area of unstained tissue. Infarct volumes were calculated from digital images of 1 mm sections and expressed as the percentage of infarct in the ipsilateral hemisphere. This method of calculating infarct volumes has been used previously and has been correlate.

15

**Preparation of CD39:** Recombinant CD39 was prepared as described<sup>11</sup>. In brief, the CD39 cDNA insert, containing the CD39 sequence and IL-2 leader, was stably transfected into CHO cells, affinity purified from conditioned medium, followed by removal of N-linked sugars. Biochemical purity was assured as described<sup>11</sup>. Doses used are indicated in the test.

20

**Measurement of Bleeding Time:** Bleeding times were measured in mice which were not subjected to experimental manipulation other than by receiving either vehicle (saline) or CD39 prepared in physiological saline and administered intravenously 5 minutes prior to the experiment. Following anesthesia, a standardized incision was made on the central dorsal tail vein, and the tail was then immersed in physiological saline at 37.5°C. Time was recorded from the moment blood was observed to emerge from the wound until cessation of blood flow<sup>29</sup>.

25

30

**Measurements of cerebral thrombosis:** <sup>111</sup>Indium-platelet

35

accumulation: Platelet accumulation was determined using  $^{111}\text{In}$  labeled platelets, collected and prepared as previously described <sup>27,30</sup>. In brief, pooled blood was collected from control mice in 3.8% sodium citrate for anticoagulation (10mL total). Platelets were isolated by differential centrifugation, first at 300 x g for 5 minutes to obtain platelet rich plasma, which was then washed three times at 2000 x g for 15 minutes in 10ml of acid/citrate/dextrose anticoagulant (ACD-A, containing 38 mmol/L citric acid, 75 mmol/L sodium citrate, and 135 mmol/L glucose). The pellet was suspended in 5 mL of ACD-A and centrifuged at 100 x g for 5 minutes to remove contaminating red blood cells, and the supernatant was collected.  $^{111}\text{In}$ -oxyquinoline (70  $\mu\text{L}$  of 1 mCi/mL, Amersham Medipysics) was added, and the suspension was shaken gently for 30 minutes at room temperature. The radiolabeled platelets were washed three times in ACD-A and resuspended in PBS, and the platelet number was adjusted to  $5 \times 10^6$  mL ( $1 \times 10^6$  counts were given to each animal). Immediately prior to insertion of the occluding suture, 0.2 mL of  $^{111}\text{In}$ -labeled platelet suspension was injected intravenously into the penile vein; at 24 hours of reperfusion, brain tissue was harvested and platelet accumulation was quantified as the ipsilateral/contralateral cpm ratio.

**Detection of Intracerebral Fibrin:** Mice were first subjected to focal cerebral ischemia and reperfusion as describe above. In order to detect fibrin by immunoblotting, mice were heparinized (1000U/mL, 0.2 mL given intravenously) about 1 minute prior to sacrifice) in order to minimize postmortem thrombosis. Following separation into right and left hemispheres and plasmin digestion to solubilize fibrin, immunoblotting for fibrin was performed as described previously<sup>31</sup> using a monoclonal

anti-fibrin IgG1 (Biodesign International, ME) that had been prepared with human fibrin-like beta peptide as immunogen. This antibody was shown to react with murine fibrin but not murine fibrinogen in preliminary experiments.

**Measurement of intracerebral hemorrhage:** ICH was quantified using a spectrophotometric assay for hemoglobin which has been recently developed and validated for use in a murine model of stroke <sup>32</sup>. In brief, mouse brains were homogenized, sonicated, centrifuged, and hemoglobin in the supernatants was converted (with Drabkin's reagent) to cyanomethemoglobin, whose concentration was assessed by measuring O.D. at 550 nm against a standard curve generated with known amounts of hemoglobin.

**Preparation of Murine Platelets:** Mice (untreated, treated with 4 mg/kg CD39, or treated with 4 mg/kg aspirin) were anesthetized and heparinized (10 U/g), prior to blood collection via cardiac puncture performed with 22 gauge, 1 cc syringe. Immediately following collection, 80  $\mu$ l 3.8% trisodium citrate was added to each mL of blood. Blood from 6-8 mice was pooled in a 15 mL tube centrifuge tube (Flacon, polypropylene). Platelet-rich plasma (PRP) was prepared with an initial whole blood centrifugation (900 g, 3 min, 20°C, no brake), and a second centrifugation of PRP (100g, 2 min) to eliminate residual erythrocytes and leukocytes. The stock suspension of PRP was maintained at room temperature. PRP platelet counts were  $400-700 \times 10^3$  platelets per  $\mu$ l.

**Platelet aggregation studies:** PRP (200  $\mu$ l) was pre-incubated (3 min, 37°C) with 100  $\mu$ l Tris-buffered saline (TSG) buffer (15 mM Tris, 134 mM NaCl, 5 mM glucose, pH 7.4) in an aggregometer cuvette (Lumiaggregometer; Chrono-



Log, Havertown, PA). After the 3 min, 37°C preincubation  
≈5.0 C 10<sup>5</sup> platelets, platelet agonist (ADP, collagen,  
sodium arachidonate) were added at the concentration  
indicated. Total volumes were adjusted to 300 µl with TSG  
5 buffer, and the aggregation response recorded for 2-4 min.  
Agonists were prepared as 100X solution: ADP was in TSG  
buffer, collagen in acidified isotonic glucose (Gormon  
Chemie, Munchen, Germany), and sodium arachidonate in 0.85%  
saline. All aggregation studies were completed within two  
10 hours of blood collection.

**Pharmacokinetic analysis:** C57/6J BL mice (6-8 weeks of age;  
maintained under specific pathogen free conditions; Jackson  
Laboratory, Bar Harbor, ME) were intravenously injected  
15 with 200 µg recombinant CD39. At the indicated times after  
injection (1h, 6h, 12h, and 24 h) mice were bled by cardiac  
puncture, PRP was prepared as described above, and %  
platelet inhibition was documented at the respective  
timepoints. Aggregometry performed on the PRP samples was  
20 performed in triplicate.

**Quantitation of Platelet Aggregation:** Area under the curve  
was estimated by multiplying the height of the curve with  
its width at half height. The former was measured from  
25 pre-simulation baseline to the middle of the highest point  
of the curve. However, when curves were less than 1/3 of  
maximal height, the lowest point of the shape change  
portion of the curve was considered baseline. Width at  
half height was extrapolated if the curve did not re-  
30 approach baseline, but was always considered 6 min (=cm) or  
less. These criteria underestimate large aggregation  
responses, and overestimate small ones. Thus we knowingly  
underestimated the effects of compounds with great  
inhibitory capacity. This approach was preferred over one  
35 that could have overemphasized inhibitory potential.

**Murine platelet aggregation:** C57/6J BL mice (6-8 weeks) were obtained from Jackson Laboratories, Bar Harbor, ME). Untreated mice, and mice treated with 4 mg/kg CD39, with 5 mg/kg aspirin or phosphate buffered saline, were anesthetized and heparinized (10 U/g), prior to blood collection via cardiac puncture; 80  $\mu$ L 3.8% trisodium citrate was added to each mL of blood. Samples from 6-8 mice were pooled and platelet-rich plasma (PRP) prepared by centrifugation (900 g, 3 min, 20°C, followed by 100 g, 2 min to eliminate residual erythrocytes and leukocytes). PRP contained 400-700  $\times 10^3$  platelets per  $\mu$ L. PRP (200  $\mu$ L) was preincubated (3 min, 37°C) with 100  $\mu$ L Tris-buffered saline (TSG) buffer (15 mM Tris, 134 mM NaCl, 5 mM glucose, pH 7.4)<sup>11,23,24</sup> in an aggregometer cuvette (Lumiaggregometer; Chrono-Log, Havertown, PA). Platelet agonists (ADP, collagen (Hormon Chemie, Munchen, Germany), or sodium arachidonate (Nu-Check Prep, Elysian, MN)) were added at the final concentrations indicated. Aggregation responses were recorded for 2-4 min, and expressed as area under the curve (height times width at  $\frac{1}{2}$  height). All experiments were completed within two hours of blood collection.

**Example 2: Murine stroke model**

A previously validated murine model of stroke injury was employed<sup>2,3,25</sup>. Anesthetized mice were maintained at 37  $\pm$  2°C during and 90 min following surgery. A midline neck incision was made and the right carotid artery exposed. Middle cerebral artery occlusion was accomplished by advancing a 13-mm heat-blunt tipped 6-0 nylon suture via an arteriotomy in the external carotid stump. The external carotid artery was cauterized to secure hemostasis, and arterial flow re-established. Carotid artery occlusion never exceeded 3 min. The occluding suture was removed after 45 min and cautery was again locally applied to

prevent bleeding at the arteriotomy site. Surgical staples were used for wound closure. Procedures for Doppler measurement of cerebral cortical blood flow, neurological score<sup>26</sup>, calculation of infarct volume, measurement of cerebral thrombosis using <sup>111</sup>In-labeled platelets<sup>2,27</sup>, detection of intracerebral fibrin<sup>2</sup>, and measurement of intracerebral hemorrhage<sup>2,28</sup> have been described in earlier section of this application.

10 **Example 3:**

Recent studies have demonstrated that CD39 inhibits ADP-mediated platelet aggregation<sup>11</sup>. To ascertain the relative potency of CD39 and another agent thought to improve outcomes following transient cerebral attacks in human (aspirin<sup>12</sup>), aggregometry studies were performed using murine platelets treated with saline (control), CD39, or aspirin. Control and aspirin-treated platelets strongly aggregated in response to challenge with either ADP (Figs. 1A & 1C) or collagen (Figs. 1B & 1D). In sharp contrast, CD39 completely abrogated the platelet aggregation response to ADP addition, and attenuated the aggregation response to collagen (inhibition was greater with a lower of collagen). Dose-response data showed an increase in the response to sodium arachidonate, the precursor of thromboxane A<sub>2</sub> was somewhat different. As expected, aspirin abrogated the platelet response to arachidonate (Fig. 1E). CD39, on the other hand, did not inhibit the initial activation phase of platelet aggregation to arachidonate, but rapidly disaggregated platelets during the initial recruitment phase. The data are quantified to show percent inhibition of platelet aggregation in response to aspirin or CD39 treatment (Fig. 1F).

Reduction in sequelae of stroke by CD39: Experiments were performed to demonstrate the therapeutic utility of

intravenously injected CD39 in stroke. CD39 inhibited platelet as well as fibrin accumulation in the ipsilateral cerebral hemisphere following induction of stroke (Figs. 3A & 3B). As postulated, the ability of CD39 to reduce thrombosis was accompanied by improved postischemic cerebral perfusion (Fig. 3A). In contrast, aspirin, when administered at a clinically relevant dose that inhibited the ex vivo response of platelets to arachidonate, did not improve postischemic cerebral blood flow (Fig. 3A). Preoperatively administered CD39 conferred a dose-dependent diminution of cerebral infarct volume (Fig. 3B). In contrast, although aspirin showed a tendency to decrease cerebral infarct volume, the effect was not statistically significant. CD39 treatment (either prior to, or up to 3 hours following stroke) reduced both neurological deficit (Fig. 3C) and mortality (Fig. 3D).

#### **Example 4**

CD39 and aspirin were examined with regard to development of intracerebral hemorrhage following stroke (Fig. 3E). Whereas aspirin increased intracerebral hemorrhage significantly, there was no statistically significant increase in intracerebral hemorrhage at any dose of CD39 tested (Fig. 3E). At these doses CD39 inhibited both platelet and fibrin accumulation and promoted an increase in postischemic blood flow (Figs. 3A, 5A & 5B). A covariate plot of cerebral infarct volume vs. intracerebral hemorrhage for each treatment indicates that aspirin is less capable of reducing infarct volume and preventing intracerebral hemorrhage than are several regimens of CD39 treatment (Fig. 4).

#### **Example 5**

To further characterize the role of endogenous CD39 in regulation of hemostasis, CD39 null mice were generated by

a gene targeting vector in which exons 3-5, containing Apyrase Conserved Regions 1-3 (ACR 1-3), were replaced with a PGKneo cassette. Homozygous null CD39 mice did not display an obvious phenotype in the unperturbed state, including normal bleeding times (Fig. 2). These bleeding times can be contrasted with unperturbed state, including normal bleeding times (Fig 2). These bleeding times can be contrasted with the marked increase in bleeding time induced by aspirin treatment, and the dose-dependent increase in bleeding time evoked by CD39. Hematologic profiles, including platelet counts, hemoglobin levels, white blood cell counts and differentials (Table 1), and PT/PTT (not shown) were normal in these mice. To test the hypothesis that a latent prothrombotic phenotype could be induced in a clinically relevant platelet-dependent model (Stroke<sup>2</sup>), mice were subjected to focal cerebral ischemia. CD39 null mice exhibited diminished blood flow following reperfusion compared with their genetically matched controls (Fig. 6A). When CD39 (200 µg/mL was given to the CD39 null mice, these "reconstituted mice" exhibited postischemic flows which were similar to untreated control mice. When these null mice were sacrificed at 24 hours, there were increased cerebral infarction volumes compared with genotype-matched control mice. CD39 null mice reconstituted with CD39 were protected in stroke, as shown by their markedly diminished infarct volumes at 24 hours (Fig. 6B). Other parameters which were measured but which did not differ between groups included neurological deficit scores, overall mortality, and intracerebral hemorrhage, measured in a spectrophotometric hemoglobin assay which we have recently validated for use in stroke<sup>32</sup> (Figs. 6C, 6D, & 6E).

#### **Example 6**

Reconstitution of CD39<sup>-/-</sup> mice with CD39: To further

characterize the contributions of endogenous CD39 to hemostasis and thrombosis, CD39<sup>-/-</sup> mice were generated by a gene targeting vector in which exons 4-6, encoding apyrase conserved regions 2-413-16, were replaced with a PGKneo cassette. Homozygous CD39<sup>-/-</sup> mice did not display an obvious phenotype in the unperturbed state. Hematological profiles were normal, including erythrocyte parameters, platelet counts, leukocyte counts and differentials, and coagulation screening tests. Bleeding times of CD39<sup>-/-</sup> mice were normal, in contrast to the markedly increased bleeding time following aspirin treatment, and a dose-dependent increase in bleeding time induced by CD39 (Fig. 2).

#### 15 **Example 7**

The next group of experiments were performed to demonstrate the utility of CD39 as a therapeutic agent in stroke. First, the antithrombotic action of CD39 was established by its ability to inhibit platelet accumulation in stroke (Fig. 5A) as well as to inhibit fibrin accumulation in the ipsilateral cerebral hemisphere (established by fibrin immunoblot (Fig. 5B)). As expected, the ability of CD39 to diminish thrombosis in stroke was accompanied by improved postischemic cerebral perfusion (Fig. 3A). In contrast, aspirin, even when used at a clinically relevant dose which inhibited the response of platelets to arachidonate ex vivo, did not improve postischemic cerebral blood flow (Fig. 3A). In terms of cerebral infarction volume, CD39 administered preoperatively conferred a dose-dependent diminution of cerebral infarct volumes, in contrast to aspirin, which only tended to decrease cerebral infarct volumes (this reduction was not statistically significant) (Fig. 3B). Similarly, CD39 reduced both neurological deficit (Fig. 3C) and mortality (Fig. 3D). Of especial importance were data in which the effects of aspirin and

CD39 were examined in terms of intracerebral hemorrhage. Although aspirin did increase intracerebral hemorrhage significantly, there was not statistically significant increase postischemic blood flow. The relationship between the ability of either aspirin, CD39, or vehicle to diminish cerebral infarction volume and their propensity to increase intracerebral hemorrhage are shown in Fig. 3.

#### Example 8

Other forms of ischemia were also studied. Because of the integral role of platelets in other forms of coagulation, thrombosis, vascular remodeling (and disorders such as pulmonary embolism, lung ischemia, limb or gut ischemia, myocardial ischemia, post surgical vasculopathy, postangioplasty stenosis, shunt/fistula remodeling or thrombosis), I have tested the effect of CD39 in another ischemic disorder involving a different vascular bed than that in the brain. For these additional studies, I have used a mouse model of lung ischemia and reperfusion to show that CD39 confers significant postischemic protection to the lung tissues and blood vessels.

In these studies, murine ischemic reperfusion model was used. In the mouse model of lung ischemia, mice were initially anesthetized intraperitoneal with 0.1 mg/mouse weight (g) of ketamine and 0.01 mg/mouse weight (g) of xylazine, following by intraperitoneal continuous infusion of one third of the initial dose per hour using a syringe pump (model 100 series, KD Scientific Inc. MA). After ensuring appropriate depth of anesthesia, mice were intubated via tracheostomy and placed on a Harvard ventilator (tidal volume=0.75 mL, respiratory rate=120/min) with room air, followed by bilateral thoracotomy. The left hilum was cross-clamped for a period of 1 hour after which the cross-clamp was released. Reperfusion proceeded for 2

hours.

For all experiments, the surgical operator was blinded by a colleague in the laboratory to the specific substance being injected (vehicle or CD39, 8 mg/kg). Experimental procedures were as follows. After one-hour ischemia followed by 2-hour reperfusion, the contralateral (right hilum was permanently ligated, so that the animal's survival and gas exchange depended solely upon the reperfused lung, and observation continued for 1 hour. As the mouse continued to be ventilated, death of the mouse was defined as a combination of (1) cessation of regular cardiac activity; (2) the apparent collapse of the left atrium; and (3) brief clonic activity indicating cessation of cerebral blood flow.

In four experiments with CD39, mouse survival was 100% following functional removal of the contralateral (nonischemic) lung from the circulation. In contrast, control (vehicle-treated) (n=7) demonstrated no survival under identical conditions. These data indicate that CD39 has a marked protective effect (reduces tissue injury and protects function) of the postischemic lung.

## Discussion

Platelet and fibrin deposition downstream of an occlusive lesion contribute significantly to the postischemic hypoperfusion and tissue injury complicating stroke. It has been demonstrated for the first time in vivo protection conferred by CD39 in this platelet-dependent thrombotic disorder. CD39 improves cerebral blood flow and reduces cerebral infarct volume when given preoperatively. In addition, CD39 confers significant cerebroprotection when administered three hours after onset of stroke. Rendering cerebroprotection at this delayed time point is significant



because these effects occurred without an increase in mortality or intracerebral hemorrhage. The CD39<sup>-/-</sup> mice had a defect in thromboregulation in that they exhibited larger infarct volume than their genotype-matched controls. The CD39<sup>-/-</sup> mice were "reconstituted" by administration of CD39, thus fulfilling Koch's postulates<sup>17</sup>.

CD39<sup>-/-</sup> mice did not have an obvious phenotype, with completely normal baseline hematological and coagulation profiles, including platelet counts. This contrasts with mice null for the protein P-selectin, where leukocytosis is apparent in unperturbed mice<sup>18</sup>. Moreover, spontaneous thrombotic events have not been observed, as reported in PAI-1 overexpressing mice<sup>19</sup>. Rather, CD39<sup>-/-</sup> mice appear to exhibit a latent prothrombotic phenotype, elicited by inducing a platelet-dependent thrombotic disorder (stroke). It is postulated that under basal conditions, vascular homeostasis may be maintained by the endothelial thromboregulators prostacyclin and nitric oxide<sup>8</sup>. However, a severe breach in vascular integrity leads to platelet accumulation and consequent fibrin deposition in the absence of CD39, as in the CD39<sup>-/-</sup> mice. Reconstitution of the animal with CD39 appears to ameliorate this defect (Figs. 6A, 6B).

Although aspirin may be of benefit in primary prevention of stroke, it does not appear to be efficacious in evolving stroke<sup>12</sup>. Moreover, some patients obtain little benefit from aspirin ("nonresponders"), even though it is efficacious in others<sup>10,20</sup>. GPIIb/IIIa antagonists are potent inhibitors of platelet aggregation, since they block a final step in platelet accumulation, i.e. fibrinogen bridging of surface glycoprotein GP IIb/IIIa receptors, thus abrogating platelet-platelet adherence. Although useful in prevention of intravascular thrombosis following

percutaneous coronary intervention, these agents have not been widely studied specifically in the setting of acute stroke. One highly specific GP IIb/IIIa antagonist, GPI-562, had potent antithrombotic effects in experimental stroke, and did reduce cerebral infarction volume, but it was associated with intracerebral hemorrhage<sup>2</sup>. Other platelet inhibitors useful in management of acute ischemic syndromes, such as ticlopidine or clopidogrel<sup>21</sup>, inhibit platelet aggregation mediated by the low affinity P2Y<sub>1</sub> ADP receptor on the platelet surface<sup>22</sup>. The data herein show that endogenous CD39 is protective in stroke, and that administration of pharmacological doses of CD39 is effective in inhibiting thrombosis and tissue injury in stroke. Since CD39 inhibits all ADP-mediated platelet aggregation via metabolic deletion of ADP from the activated platelet releasate, it may be more potent than the ADP-receptor blockers currently in use.

The basis for the apparent superiority of CD39 to aspirin may be that it induces more potent inhibition of ADP-induced platelet aggregation. This latter mechanism is more efficient in platelet-induced platelet recruitment than the arachidonate/thromboxane pathway. Moreover, while platelet reactivity to low-dose collagen is inhibited by CD39, platelets do respond to higher doses of collagen. In contrast, aspirin had little effect on platelet reactivity at any collagen dose. The hemostatic effects of agonist-induced pathways are likely to overlap with considerable redundancy in vivo. However, the experimental data indicate that aspirin resulted in more bleeding in response to vein injury, or stroke, than did CD39. Perhaps the initial layer of platelets that adheres to an injured vessel wall is essential for hemostasis, but in stroke, ADP-mediated recruitment of platelets into an evolving thrombus results in intravascular occlusion. CD39

disaggregates platelets that have already responded to an agonist, but it does not have a deleterious effect on primary hemostasis.

5 It has been previously demonstrated that microvascular thrombosis is a continuing phenomenon after the onset of stroke<sup>2</sup>. Therefore, this ongoing process can be modulated by therapeutics with CD39, even three hours after stroke induction. The data presented herein are especially  
10 pertinent in the setting of clinical observations of increased intracerebral hemorrhage when thrombolytic agents are administered beyond three hours following stroke onset<sup>6</sup>. Thus, the results may constitute a possible new approach to antithrombotic therapy, based upon metabolism  
15 of a major agonist for vascular occlusion platelet-released ADP.

It was hypothesized that a latent prothrombotic phenotype could be identified in a clinically relevant platelet-  
20 dependent stroke model<sup>2</sup>. Indeed, CD39<sup>-/-</sup> mice, subjected to focal cerebral ischemia, did exhibit diminished blood flow following reperfusion as compared to genetically matched controls (Fig. 6A). When CD39 (8 mg/kg) was administered to the CD39<sup>-/-</sup> mice, these mice were  
25 "reconstituted" as shown by a postischemic blood flow similar to untreated controls. Furthermore, CD39<sup>-/-</sup> mice demonstrated increased cerebral infarction volume as compared to genotype-matched controls following induced stroke (Fig. 6B). CD39<sup>-/-</sup> mice "reconstituted" with CD39  
30 had markedly diminished infarct volume, indicating a protective effect of CD39. Other parameters (neurological deficit scores, overall mortality, and intracerebral hemorrhage) did not differ between groups (Figs. 6C, 6D, & 6E). Moreover, CD39 should inhibit only platelet/platelet  
35 recruitment mediated ADP, and attenuate recruitment by

other agonists such as collagen or arachidonate. As CD39 does not interfere with the primary GPIb-mediated platelet adhesive event at the site of vessel damage, CD39 should not prevent a subsequent layer of platelets from forming at sites of vascular damage and therefore not interfere with hemostatic regulatory mechanisms required for prevention of intracerebral hemorrhage. I also hypothesized that alternative methods of inhibiting platelet-mediated amplification of intravascular thrombosis should provide a strategy in which primary hemostasis at sites of vascular injury may be maintained, in the setting of inhibition of platelet-mediated autoamplification (recruitment).

b

The experimental data indicate that platelet and fibrin deposition in the ipsilateral cerebral hemisphere contribute significantly to the postischemic hypoperfusion and tissue injury which occur in stroke. These studies identify for the first time an in vivo protective role conferred by CD39 in a platelet-dependent thrombotic disorder (stroke). CD39, which we show to be a potent inhibitor of ADP-induced platelet aggregation, also has an extended in vivo half life (elimination half-time in mice is 2 days<sup>11</sup>). Not only does it improve cerebral blood flow and reduce cerebral infarction volumes when given preoperatively, but it also confers significant cerebroprotection when given 3 hours after the onset of stroke. The effect of this agent in conferring cerebroprotection at this delayed time point is both novel and important because the cerebroprotective effects occurred without increasing intracerebral hemorrhage or mortality. The CD39 null mice, which exhibit larger infarct volumes than their genotype controls, were rescued by the administration of CD39, fulfilling Koch's postulates<sup>32</sup> for demonstration that endogenous CD39 is a major thromboregulator.

CD39 is a 95 kD integral endothelial cell membrane glycoprotein, comprised of two membrane spanning domains, a centrally located hydrophobic domain, and four putative ADPase (apyrase) domains which are highly conserved<sup>11</sup>. CD39 is constitutively expressed on vascular endothelial cells, and appears to exert an important antithrombotic activity on the endothelial cell surface. This enzyme degrades nucleotide tri- and diphosphates (but not monophosphates), and hence its expression at the endothelial surface significantly blunts the ADP-mediated recruitment phase of platelet reactivity<sup>11</sup>. In vitro studies have shown that COS cells transfected with the cDNA encoding human CD39 acquired the ability to inhibit ADP-induced platelet aggregation<sup>9</sup>. As the initial step toward developing a potentially useful antiplatelet therapeutic agent, a recombinant soluble form of CD39 was prepared by transfecting CHO cells with a cDNA construct containing the four apyrase domains but lacking the two transmembrane regions of native CD39 and introducing a leader sequence. The resulting peptide, isolated from conditioned medium was affinity purified and shown to retain potent apyrase activity, and to have an elimination half-time in mice of 2 days<sup>11</sup>. It was this peptide, CD39, which was used in the experiments described here. These studies confirm the ex vivo platelet inhibitory activity of CD39. However, the current results extend the initial observations in two ways: 1) I demonstrated platelet inhibitory activity after administration in vivo; and 2) I documented the effect of CD39 on primary hemostasis (dose-dependent increase in bleeding time, and reduction of thrombosis in stroke).

In addition to demonstrating the effects of pharmacological doses of CD39, to our knowledge, the current studies are the first to characterize the properties of CD39 null mice.

These mice do not have an obvious phenotype. Unlike mice null for other unrelated alleles, such as P-selectin, in which leukocytosis is apparent in unperturbed mice<sup>1</sup>, baseline hematologic and coagulation profiles in these mice are completely normal (including platelet counts). In addition, I have not observed spontaneous thrombotic events, such as those seen in PAI-1 overexpressing mice<sup>33</sup> which may exhibit spontaneous ischemic events resulting in lost digits or the tip of the tail. Rather, CD39 null mice to exhibit a latent prothrombotic phenotype. By inducing a platelet-dependent thrombotic disorder (stroke), I was able to elicit differences between appropriate genetic control mice and CD39 null mice.

There is an important point to be considered in the setting of the data presented herein. We and others have previously shown that in studies of mice, uniformity of background strain is critical for stroke research. Importantly, baseline cerebral infarct volumes were smaller in the CD39 mice on the 129/C57Bl background than in control mice which were pure C47Bl/6J. Because of limitations in time for backbreeding, the CD39 null mice which were used for the current experiments are on a mixed background (C57Bl/129J). Therefore, genotype-matched control mice were essential to establish the latent prothrombotic phenotype of these mice and their relative susceptibility to cerebral infarction. Data were also obtained or derived from experiments using pure C57Bl/6J mice. As one would expect from published literature, C57Bl/6J mice have larger absolute cerebral infarction volumes than "F1 control" mice comprised of a mixed C57Bl/6J/129J background; therefore, it is important to compare data only with genotype-matched controls. It has been shown that there are reproducible strain-related differences in susceptibility to stroke. Thus, 129J is a

particularly resistant strain, and C57Bl is a particularly susceptible strain<sup>25,34,35</sup>. For this reason, genetically matched controls were performed.

5 Why should CD39 constitute a better therapeutic strategy in stroke than other anti-platelet agents, with greater or lesser efficacy different mechanisms of actions? Aspirin, which has clear benefits in terms of primary prevention of stroke, has not been shown to be efficacious for evolving  
10 stroke<sup>12</sup>. Furthermore, there are a group of patients who are aspirin nonresponders<sup>36</sup>, who obtain little benefit from aspirin even where it is efficacious in others. GPIIb/IIIa antagonist which was tested in stroke, GPI-562, had potent antithrombotic action and could diminished cerebral  
15 infarction volumes<sup>2</sup>. However, the therapeutic window for this agent was narrow. Thus only modest increases in dosage were associated with unacceptably high rates of intracerebral hemorrhage<sup>2</sup>. Although not specifically tested in current experiments, other antiplatelet agents  
20 may be useful in the treatment of evolving stroke. This includes agents such as ticlodipine or clopidogrel, both of which inhibit platelet aggregation mediated by the low-affinity type II ADP receptor on the platelet surface. Experiments with the CD39 null mice and recombinant CD39  
25 show that endogenous CD39 is protective, and the administration of pharmacologic doses of CD39 are effective in terms of inhibiting thrombosis and tissue injury during stroke. It remains to be seen whether sol39 is more potent than the other ADP-receptor blockers, but CD39 should  
30 inhibit all ADP-mediated platelet aggregation. Unlike ticlodipine or clopidogrel, CD39 metabolically deletes ADP from an activated platelet releasate.

Data obtained in the experiments give insights into reasons  
35 for the superiority of CD39 to aspirin. First, it is

clearly a more potent antiplatelet agent with respect to ADP-induced platelet aggregation, which may be of more importance in platelet-induced platelet recruitment than the arachidonate/thromboxane axis. Secondly, CD39 did not  
5 inhibit reactivity of platelets to low-dose collagen, although at high dose collagen, there was minor inhibition of collagen-induced platelet reactivity. Aspirin had no effect on collagen-reactivity of platelet at any collagen dose. The hemostatic effects agonist-induced pathways are  
10 likely to overlap with considerable complexity *in vivo*; however, experimental data on bleeding time and intracerebral hemorrhage indicated that aspirin was more potent as an anticoagulant in response to specific stimuli (such as cutting a vein, or stroke) than was CD39. Perhaps  
15 the initial layer of platelets which is laid down is essential for hemostasis, but the augmented accumulation of platelets via recruitment results in the intravascular obstruction which is deleterious in stroke. In this regard, CD39 is capable of disaggregating platelets which  
20 have already aggregated in response to all agonists.

How might CD39 prove to be therapeutically useful? It has been shown that the therapeutic index of CD39 is high, i.e., even twice the effective dose does not increase the  
25 occurrence of intracerebral hemorrhage. Furthermore, when given even 3 hours following stroke, therapeutic efficacy is apparent. These data confirm previous research in which microvascular thrombosis was demonstrated to be an ongoing process after the onset of stroke. Inhibition of ongoing  
30 microvascular thrombosis is the therapeutic target of the current CD39 strategy. These results are especially important in light of current clinical observation, which show increased intracerebral hemorrhage and mortality if a thrombolytic agent is administered beyond three hours  
35 following the onset of stroke. Even in the best of



circumstances, few patients arrive at an emergency room in sufficient time to qualify for thrombolytic therapy<sup>6</sup>. An extended time window for administration of a therapeutically useful agent may be an important first step towards improving the current limited treatment paradigms for evolving stroke. CD 39 may also have an inhibiting effect on white blood cell accumulation or leukocyte accumulation

**Table 1:** Hematological profiles of CD39<sup>-/-</sup> and genotype-matched control mice. N=f for each group.

Table 1. Comparison of Blood Cell Components in Wildtype versus CD39-deficient Mice.

Strain	Hgb (mg/dl)	WBC (cells/ $\mu$ l x 10 <sup>3</sup> )	Plts (cells/ $\mu$ l x 10 <sup>3</sup> )	Segs (cells /100WBCs)	Bands (cells /100WBCs)	Lymphs (cells /100WBCs)	Monos (cells /100WBCs)	Eos (cells /100WBCs)
CD39 +/+	13.6 $\pm$ 1.25	5.4 $\pm$ 0.74	799 $\pm$ 98.0	42 $\pm$ 2.0	1 $\pm$ 0.20	52 $\pm$ 2.4	5.2 $\pm$ 0.66	0.8 $\pm$ 0.37
CD39 -/-	13.2 $\pm$ 0.57	3.5 $\pm$ 0.40	776 $\pm$ 52.2	32.6 $\pm$ 3.4	0.4 $\pm$ 0.24	61.8 $\pm$ 3.2	5 $\pm$ 0.45	0.2 $\pm$ 0.2
p-value	0.47	0.11	0.82	0.39	0.37	0.28	0.85	0.21

REFERENCES

1. Bronner, L. L., et al. (1995) "Primary prevention of stroke" N. Engl. J. Med. **333(21)**: 1392-1400;
2. Choudhri, T. F., et al. (1998) "Reduced microvascular thrombosis and improved outcome in acute murine stroke by inhibiting GP IIb/IIIa receptor-mediated platelet aggregation" J. Clin. Invest., **102**: 1301-1310;
3. Connolly, E. S. Jr., et al. (1996) "Cerebral protection in homozygous null ICAM-1 mice after middle cerebral artery occlusion. Role of neutrophil adhesion in the pathogenesis of stroke" J. Clin. Invest., **97**: 209-216;
4. Connolly, E. S. Jr., et al. (1997) "Exacerbation of cerebral injury in mice which express the P-selectin gene: identification of P-selectin blockade as a new target for the treatment of stroke" Circ. Res., **81**: 304-310;
5. Wardlaw, J. M., et al. (1997) "Systematic review of evidence on thrombolytic therapy for acute ischemic stroke [see comments]" Lancet., **350**: 607-614;
6. Chiu, D., et al. (1998) "Intravenous tissue plasminogen activator for acute ischemic stroke: feasibility, safety, and efficacy in the first year of clinical practice" Stroke, **29**: 18-22;
7. Marcus, A. J. & Safeir, L. B. (1993) "Thromboregulation: multicellular modulation of platelet reactivity in hemostasis and thrombosis"

FASEB J., 7: 516-522;

8. Marcus, A. J. (1999) "in Inflammation: Basic Principles and Clinical Correlates" (EDS Gallin, J.I. & Snyderman, R.) 77-95 (Lippincott, Williams & Wilkins, Philadelphia;
9. Marcus, A. J., et al. (1997) "The endothelial cell ecto-ADPase responsible for inhibition of platelet function is CD39" J. Clin. Invest., **99**: 1351-1360;
10. Harbison, J. W. *Am. J. Health Syst. Pharm* **55**, S17-S20 (1998).
11. Gayle, R. B., et al. (1998) "Inhibition of platelet function by recombinant soluble ecto-ADPase/CD39" J. Clin. Invest, **101**: 1851-1859;
12. Dippel, D. (1998) "The results of CAPRIE, IST, and CAST" *Thrombosis Res.*, **92**: S13-S16;
13. Handa, M. & Guidotti, G. *Biochem. Biophys. Res. Commun.* **218**, 916-923 (1996).
14. Wang, T. F. & Guidotti, G. *J. Biol. Chem.* **271**, 9898-9901 (1996).
15. Maliszewski, C. R., et al. (1994) *J. Immunol.*, **153**: 3574-3583;
16. Schoenborn, M. A., et al. (1998) " Cytogen Cell Gen., **81(3-4)**: 287-280;
17. Koch, R. *Verhandlungen des X. Internationalem*

Medizinischen Congresses Berlin 1: 35-47  
(1891). (Abstract)

18. Mayadas, T. N., et al. (1993) "Leukocyte rolling and  
5 extravasation are severely compromised in P-selection  
deficient mice" Cell, **74(3)**: 541-554;
19. Erickson, L. A., et al. (1990) Nature, **346**: 74-76;
- 10 20. Grotenmeyer, K. H. Thrombosis Res., **63**: 587-593  
(1991);
21. CAPRIE Steering Committee, Lancet., **348**: 1329-1339  
(1996);
- 15 22. Hechler, B., et al. (1998) Br. J. Haematol., **103**: 858-  
866;
23. Broekmann, M. J., et al. (1991) Blood, **78**: 1033-1040;
- 20 24. Marcus, A. J., et al. (1991) J. Clin. Invest., **88**:  
1690-1696;
- 25 25. Connolly, E. S. Jr., et al. (1996) "Procedural and  
strain-related variables significantly affect outcome  
in a murine model of focal cerebral ischemia"  
Neurosurg., **38(3)**: 523-532;
- 30 26. Huang, Z., et al. (1994) "Effects of cerebral ischemia  
in mice deficient neuronal nitric oxide synthase"  
Science, **265**: 1883-1885;
27. Naka, Y., et al. (1995) "Enhanced preservation of  
orthotopically transplanted rat lungs by nitroglycerin

but not hydralazine. Requirement for graft vascular homeostasis beyond harvest vasodilation" Circ. Res., **76**: 900-906;

- 5 28. Choudhri, T. F., et al. (1997) "Use of a spectrophotometric hemoglobin assay to objectively quantify intracerebral hemorrhage in mice" Stroke, **28**: 2296-2302; p
- 10 29. Bowie E. J. W., et al. (1974) "Progress in Hemostasis and Thrombosis" The Bleeding Time, in Spaet TH (ed) 2d Ed, New York, Grune & Statton, pp249-271;
- 15 30. Mizutani H, et al. (1990) "Analyses of thrombocytopenia in idiopathic thrombocytopenic purpura-prone mice by platelet experiments between (NZW X BXSB)F1 and normal mice" Blood, 75:1809-1912;
- 20 31. Lawson C. A., et al. (1997) "Monocytes and tissue factor promote thrombosis in a murine model of oxygen deprivation" J. Clin. Invest., 99: 1729-1738;
- 25 32. Kock R. (1890) "Ueber bakteriologische Forschung" In VerhX Int Med Congr Berlin, 1892:35-30;
- 30 33. Eitzman D. T. (1996) "Bleomycin-induced pulmonary fibrosis in transgenic mice that either lack or overexpress the murine plasminogen activator inhibitor-gene" J. Clin. Invest., 97:232-237;
34. Maeda K, et al. (1998) "Differences in the cerebrovascular anatomy of c57black/6 and SV129 mice" Neuroreport, 9(7):1317-1319;
- 35 35. Majid A., et al. (1999) "Intrinsic, hemodynamic-

independent differences in vulnerability to permanent focal cerebral ischemia in common mutant mouse strains" 24th American Heart Association International Conference on Stroke and Cerebral CXJO-XXPY;

5

36. Buchanan M. R., et al. (1995) "Individual variation in the effects of ASA on platelet function: Implication for the use of ASA clinically" Cardiovasc. Medicine, 11(3):221-227.

10

11  
12  
13  
14  
15  
16  
17  
18  
19  
20  
21  
22  
23  
24  
25  
26  
27  
28  
29  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60  
61  
62  
63  
64  
65  
66  
67  
68  
69  
70  
71  
72  
73  
74  
75  
76  
77  
78  
79  
80  
81  
82  
83  
84  
85  
86  
87  
88  
89  
90  
91  
92  
93  
94  
95  
96  
97  
98  
99  
100  
101  
102  
103  
104  
105  
106  
107  
108  
109  
110  
111  
112  
113  
114  
115  
116  
117  
118  
119  
120  
121  
122  
123  
124  
125  
126  
127  
128  
129  
130  
131  
132  
133  
134  
135  
136  
137  
138  
139  
140  
141  
142  
143  
144  
145  
146  
147  
148  
149  
150  
151  
152  
153  
154  
155  
156  
157  
158  
159  
160  
161  
162  
163  
164  
165  
166  
167  
168  
169  
170  
171  
172  
173  
174  
175  
176  
177  
178  
179  
180  
181  
182  
183  
184  
185  
186  
187  
188  
189  
190  
191  
192  
193  
194  
195  
196  
197  
198  
199  
200  
201  
202  
203  
204  
205  
206  
207  
208  
209  
210  
211  
212  
213  
214  
215  
216  
217  
218  
219  
220  
221  
222  
223  
224  
225  
226  
227  
228  
229  
230  
231  
232  
233  
234  
235  
236  
237  
238  
239  
240  
241  
242  
243  
244  
245  
246  
247  
248  
249  
250  
251  
252  
253  
254  
255  
256  
257  
258  
259  
260  
261  
262  
263  
264  
265  
266  
267  
268  
269  
270  
271  
272  
273  
274  
275  
276  
277  
278  
279  
280  
281  
282  
283  
284  
285  
286  
287  
288  
289  
290  
291  
292  
293  
294  
295  
296  
297  
298  
299  
300  
301  
302  
303  
304  
305  
306  
307  
308  
309  
310  
311  
312  
313  
314  
315  
316  
317  
318  
319  
320  
321  
322  
323  
324  
325  
326  
327  
328  
329  
330  
331  
332  
333  
334  
335  
336  
337  
338  
339  
340  
341  
342  
343  
344  
345  
346  
347  
348  
349  
350  
351  
352  
353  
354  
355  
356  
357  
358  
359  
360  
361  
362  
363  
364  
365  
366  
367  
368  
369  
370  
371  
372  
373  
374  
375  
376  
377  
378  
379  
380  
381  
382  
383  
384  
385  
386  
387  
388  
389  
390  
391  
392  
393  
394  
395  
396  
397  
398  
399  
400  
401  
402  
403  
404  
405  
406  
407  
408  
409  
410  
411  
412  
413  
414  
415  
416  
417  
418  
419  
420  
421  
422  
423  
424  
425  
426  
427  
428  
429  
430  
431  
432  
433  
434  
435  
436  
437  
438  
439  
440  
441  
442  
443  
444  
445  
446  
447  
448  
449  
450  
451  
452  
453  
454  
455  
456  
457  
458  
459  
460  
461  
462  
463  
464  
465  
466  
467  
468  
469  
470  
471  
472  
473  
474  
475  
476  
477  
478  
479  
480  
481  
482  
483  
484  
485  
486  
487  
488  
489  
490  
491  
492  
493  
494  
495  
496  
497  
498  
499  
500  
501  
502  
503  
504  
505  
506  
507  
508  
509  
510  
511  
512  
513  
514  
515  
516  
517  
518  
519  
520  
521  
522  
523  
524  
525  
526  
527  
528  
529  
530  
531  
532  
533  
534  
535  
536  
537  
538  
539  
540  
541  
542  
543  
544  
545  
546  
547  
548  
549  
550  
551  
552  
553  
554  
555  
556  
557  
558  
559  
560  
561  
562  
563  
564  
565  
566  
567  
568  
569  
570  
571  
572  
573  
574  
575  
576  
577  
578  
579  
580  
581  
582  
583  
584  
585  
586  
587  
588  
589  
590  
591  
592  
593  
594  
595  
596  
597  
598  
599  
600  
601  
602  
603  
604  
605  
606  
607  
608  
609  
610  
611  
612  
613  
614  
615  
616  
617  
618  
619  
620  
621  
622  
623  
624  
625  
626  
627  
628  
629  
630  
631  
632  
633  
634  
635  
636  
637  
638  
639  
640  
641  
642  
643  
644  
645  
646  
647  
648  
649  
650  
651  
652  
653  
654  
655  
656  
657  
658  
659  
660  
661  
662  
663  
664  
665  
666  
667  
668  
669  
670  
671  
672  
673  
674  
675  
676  
677  
678  
679  
680  
681  
682  
683  
684  
685  
686  
687  
688  
689  
690  
691  
692  
693  
694  
695  
696  
697  
698  
699  
700  
701  
702  
703  
704  
705  
706  
707  
708  
709  
710  
711  
712  
713  
714  
715  
716  
717  
718  
719  
720  
721  
722  
723  
724  
725  
726  
727  
728  
729  
730  
731  
732  
733  
734  
735  
736  
737  
738  
739  
740  
741  
742  
743  
744  
745  
746  
747  
748  
749  
750  
751  
752  
753  
754  
755  
756  
757  
758  
759  
760  
761  
762  
763  
764  
765  
766  
767  
768  
769  
770  
771  
772  
773  
774  
775  
776  
777  
778  
779  
780  
781  
782  
783  
784  
785  
786  
787  
788  
789  
790  
791  
792  
793  
794  
795  
796  
797  
798  
799  
800  
801  
802  
803  
804  
805  
806  
807  
808  
809  
810  
811  
812  
813  
814  
815  
816  
817  
818  
819  
820  
821  
822  
823  
824  
825  
826  
827  
828  
829  
830  
831  
832  
833  
834  
835  
836  
837  
838  
839  
840  
841  
842  
843  
844  
845  
846  
847  
848  
849  
850  
851  
852  
853  
854  
855  
856  
857  
858  
859  
860  
861  
862  
863  
864  
865  
866  
867  
868  
869  
870  
871  
872  
873  
874  
875  
876  
877  
878  
879  
880  
881  
882  
883  
884  
885  
886  
887  
888  
889  
890  
891  
892  
893  
894  
895  
896  
897  
898  
899  
900  
901  
902  
903  
904  
905  
906  
907  
908  
909  
910  
911  
912  
913  
914  
915  
916  
917  
918  
919  
920  
921  
922  
923  
924  
925  
926  
927  
928  
929  
930  
931  
932  
933  
934  
935  
936  
937  
938  
939  
940  
941  
942  
943  
944  
945  
946  
947  
948  
949  
950  
951  
952  
953  
954  
955  
956  
957  
958  
959  
960  
961  
962  
963  
964  
965  
966  
967  
968  
969  
970  
971  
972  
973  
974  
975  
976  
977  
978  
979  
980  
981  
982  
983  
984  
985  
986  
987  
988  
989  
990  
991  
992  
993  
994  
995  
996  
997  
998  
999  
1000  
1001  
1002  
1003  
1004  
1005  
1006  
1007  
1008  
1009  
1010  
1011  
1012  
1013  
1014  
1015  
1016  
1017  
1018  
1019  
1020  
1021  
1022  
1023  
1024  
1025  
1026  
1027  
1028  
1029  
1030  
1031  
1032  
1033  
1034  
1035  
1036  
1037  
1038  
1039  
1040  
1041  
1042  
1043  
1044  
1045  
1046  
1047  
1048  
1049  
1050  
1051  
1052  
1053  
1054  
1055  
1056  
1057  
1058  
1059  
1060  
1061  
1062  
1063  
1064  
1065  
1066  
1067  
1068  
1069  
1070  
1071  
1072  
1073  
1074  
1075  
1076  
1077  
1078  
1079  
1080  
1081  
1082  
1083  
1084  
1085  
1086  
1087  
1088  
1089  
1090  
1091  
1092  
1093  
1094  
1095  
1096  
1097  
1098  
1099  
1100  
1101  
1102  
1103  
1104  
1105  
1106  
1107  
1108  
1109  
1110  
1111  
1112  
1113  
1114  
1115  
1116  
1117  
1118  
1119  
1120  
1121  
1122  
1123  
1124  
1125  
1126  
1127  
1128  
1129  
1130  
1131  
1132  
1133  
1134  
1135  
1136  
1137  
1138  
1139  
1140  
1141  
1142  
1143  
1144  
1145  
1146  
1147  
1148  
1149  
1150  
1151  
1152  
1153  
1154  
1155  
1156  
1157  
1158  
1159  
1160  
1161  
1162  
1163  
1164  
1165  
1166  
1167  
1168  
1169  
1170  
1171  
1172  
1173  
1174  
1175  
1176  
1177  
1178  
1179  
1180  
1181  
1182  
1183  
1184  
1185  
1186  
1187  
1188  
1189  
1190  
1191  
1192  
1193  
1194  
1195  
1196  
1197  
1198  
1199  
1200  
1201  
1202  
1203  
1204  
1205  
1206  
1207  
1208  
1209  
1210  
1211  
1212  
1213  
1214  
1215  
1216  
1217  
1218  
1219  
1220  
1221  
1222  
1223  
1224  
1225  
1226  
1227  
1228  
1229  
1230  
1231  
1232  
1233  
1234  
1235  
1236  
1237  
1238  
1239  
1240  
1241  
1242  
1243  
1244  
1245  
1246  
1247  
1248  
1249  
1250  
1251  
1252  
1253  
1254  
1255  
1256  
1257  
1258  
1259  
1260  
1261  
1262  
1263  
1264  
1265  
1266  
1267  
1268  
1269  
1270  
1271  
1272  
1273  
1274  
1275  
1276  
1277  
1278  
1279  
1280  
1281  
1282  
1283  
1284  
1285  
1286  
1287  
1288  
1289  
1290  
1291  
1292  
1293  
1294  
1295  
1296  
1297  
1298  
1299  
1300  
1301  
1302  
1303  
1304  
1305  
1306  
1307  
1308  
1309  
1310  
1311  
1312  
1313  
1314  
1315  
1316  
1317  
1318  
1319  
1320  
1321  
1322  
1323  
1324  
1325  
1326  
1327  
1328  
1329  
1330  
1331  
1332  
1333  
1334  
1335  
1336  
1337  
1338  
1339  
1340  
1341  
1342  
1343  
1344  
1345  
1346  
1347  
1348  
1349  
1350  
1351  
1352  
1353  
1354  
1355  
1356  
1357  
1358  
1359  
1360  
1361  
1362  
1363  
1364  
1365  
1366  
1367  
1368  
1369  
1370  
1371  
1372  
1373  
1374  
1375  
1376  
1377  
1378  
1379  
1380  
1381  
1382  
1383  
1384  
1385  
1386  
1387  
1388  
1389  
1390  
1391  
1392  
1393  
1394  
1395  
1396  
1397  
1398  
1399  
1400  
1401  
1402  
1403  
1404  
1405  
1406  
1407  
1408  
1409  
1410  
1411  
1412  
1413  
1414  
1415  
1416  
1417  
1418  
1419  
1420  
1421  
1422  
1423  
1424  
1425  
1426  
1427  
1428  
1429  
1430  
1431  
1432  
1433  
1434  
1435  
1436  
1437  
1438  
1439  
1440  
1441  
1442  
1443  
1444  
1445  
1446  
1447  
1448  
1449  
1450  
1451  
1452  
1453  
1454  
1455  
1456  
1457  
1458  
1459  
1460  
1461  
1462  
1463  
1464  
1465  
1466  
1467  
1468  
1469  
1470  
1471  
1472  
1473  
1474  
1475  
1476  
1477  
1478  
1479  
1480  
1481  
1482  
1483  
1484  
1485  
1486  
1487  
1488  
1489  
1490  
1491  
1492  
1493  
1494  
1495  
1496  
1497  
1498  
1499  
1500  
1501  
1502  
1503  
1504  
1505  
1506  
1507  
1508  
1509  
1510  
1511  
1512  
1513  
1514  
1515  
1516  
1517  
1518  
1519  
1520  
1521  
1522  
1523  
1524  
1525  
1526  
1527  
1528  
1529  
1530  
1531  
1532  
1533  
1534  
1535  
1536  
1537  
1538  
1539  
1540  
1541  
1542  
1543  
1544  
1545  
1546  
1547  
1548  
1549  
1550  
1551  
1552  
1553  
1554  
1555  
1556  
1557  
1558  
1559  
1560  
1561  
1562  
1563  
1564  
1565  
1566  
1567  
1568  
1569  
1570  
1571  
1572  
1573  
1574  
1575  
1576  
1577  
1578  
1579  
1580  
1581  
1582  
1583  
1584  
1585  
1586  
1587  
1588  
1589  
1590  
1591  
1592  
1593  
1594  
1595  
1596  
1597  
1598  
1599  
1600  
1601  
1602  
1603  
1604  
1605  
1606  
1607  
1608  
1609  
1610  
1611  
1612  
1613  
1614  
1615  
1616  
1617  
1618  
1619  
1620  
1621  
1622  
1623  
1624  
1625  
1626  
1627  
1628  
1629  
1630  
1631  
1632  
1633  
1634  
1635  
1636  
1637  
1638  
1639  
1640  
1641  
1642  
1643  
1644  
1645  
1646  
1647  
1648  
1649  
1650  
1651  
1652  
1653  
1654  
1655  
1656  
1657  
1658  
1659  
1660  
1661  
1662  
1663  
1664  
1665  
1666  
1667  
1668  
1669  
1670  
1671  
1672  
1673  
1674  
1675  
1676  
1677  
1678  
1679  
1680  
1681  
1682  
1683  
1684  
1685  
1686  
1687  
1688  
1689  
1690  
1691  
1692  
1693  
1694  
1695  
1696  
1697  
1698  
1699  
1700  
1701  
1702  
1703  
1704  
1705  
1706  
1707  
1708  
1709  
1710  
1711  
1712  
1713  
1714  
1715  
1716  
1717  
1718  
1719  
1720  
1721  
1722  
1723  
1724  
1725  
1726  
1727  
1728  
1729  
1730  
1731  
1732  
1733  
1734  
1735  
1736  
1737  
1738  
1739  
1740  
1741  
1742  
1743  
1744  
1745  
1746  
1747  
1748  
1749  
1750  
1751  
1752  
1753  
1754  
1755  
1756  
1757  
1758  
1759  
1760  
1761  
1762  
1763  
1764  
1765  
1766  
1767  
1768  
1769  
1770  
1771  
1772  
1773  
1774  
1775  
1776  
1777  
1778  
1779  
1780  
1781  
1782  
1783  
1784  
1785  
1786  
1787  
1788  
1789  
1790  
1791  
1792  
1793  
1794  
1795  
1796  
1797  
1798  
1799  
1800  
1801  
1802  
1803  
1804  
1805  
1806  
1807  
1808  
1809  
1810  
1811  
1812  
1813  
1814  
1815  
1816  
1817  
1818  
1819  
1820  
1821  
1822  
1823  
1824  
1825  
1826  
1827  
1828  
1829  
1830  
1831  
1832  
1833  
1834  
1835  
1836  
1837  
1838  
1839  
1840  
1841  
1842  
1843  
1844  
1845  
1846  
1847  
1848  
1849  
1850  
1851  
1852  
1853  
1854  
1855  
1856  
1857  
1858  
1859  
1860  
1861  
1862  
1863  
1864  
1865  
1866  
1867  
1868  
1869  
1870  
1871  
1872  
1873  
1874  
1875  
1876  
1877  
1878  
1879  
1880  
1881  
1882  
1883  
1884  
1885  
1886  
1887  
1888  
1889  
1890  
1891  
1892  
1893  
1894  
1895  
1896  
1897  
1898  
1899  
1900  
1901  
1902  
1903  
1904  
1905  
1906  
1907  
1908  
1909  
1910  
1911  
1912  
1913  
1914  
1915  
1916  
1917  
1918  
1919  
1920  
1921  
1922  
1923  
1924  
1925  
1926  
1927  
1928  
1929  
1930  
1931  
1932  
1933  
1934  
1935  
1936  
1937  
1938  
1939  
1940  
1941  
1942  
1943  
1944  
1945  
1946  
1947  
1948  
1949  
1950  
1951  
1952  
1953  
1954  
1955  
1956  
1957  
1958  
1959  
1960  
1961  
1962  
1963  
1964  
1965  
1966  
1967  
1968  
1969  
1970  
1971  
1972  
1973  
1974  
1975  
1976  
1977  
1978  
1979  
1980  
1981  
1982  
1983  
1984  
1985  
1986  
1987  
1988  
1989  
1990  
1991  
1992  
1993  
1994  
1995  
1996  
1997  
1998  
1999  
2000  
2001  
2002  
2003  
2004  
2005  
2006  
2007  
2008  
2009  
2010  
2011  
2012  
2013  
2014  
2015  
2016  
2017  
2018  
2019  
2020  
2021  
2022  
2023  
2024  
2025  
2026  
2027  
2028  
2029  
2030  
2031  
2032  
2033  
2034  
2035  
2036  
2037  
2038  
2039  
2040  
2041  
2042  
2043  
2044  
2045  
2046  
2047  
2048  
2049  
2050  
2051  
2052  
2053  
2054  
2055  
2056  
2057  
2058  
2059  
2060  
2061  
2062  
2063  
2064  
2065  
2066  
2067  
2068  
2069  
2070  
2071  
2072  
2073  
2074  
2075  
2076  
2077  
2078  
2079  
2080  
2081  
2082  
2083  
2084  
2085  
2086  
2087  
2088  
2089  
2090  
2091  
2092  
2093  
2094  
2095  
2096  
2097  
2098  
2099  
2100  
2101  
2102  
2103  
2104  
2105  
2106  
2107  
2108  
2109  
2110  
2111  
2112  
2113  
2114  
2115  
2116  
2117  
2118  
2119  
2120  
2121  
2122  
2123  
2124  
2125  
2126  
2127  
2128  
2129  
2130  
2131  
2132  
2133  
2134  
2135  
2136  
2137  
2138  
2139  
2140  
2141  
2142  
2143  
2144  
2145  
2146  
2147  
2148  
2149  
2150  
2151  
2152  
2153  
2154  
2155  
2156  
2157  
2158  
2159  
2160  
2161  
2162  
2163  
2164  
2165  
2166  
2167  
2168  
2169  
2170  
2171  
2172  
2173  
2174  
2175  
2176  
2177  
2178  
2179  
2180  
2181  
2182  
2183  
2184  
2185  
2186  
2187  
2188  
2189  
2190  
2191  
2192  
2193  
2194  
2195  
2196  
2197  
2198  
2199  
2200  
2201  
2202  
2203  
2204  
2205